Brief: Vigil Neuroscience Expands VGl101 Phase 1 Trial To Australia

Vigil Neuroscience

07/06/2022 12:25

June 7 (Reuters) - Vigil Neuroscience Inc  VIGL.O :
    * VIGIL NEUROSCIENCE EXPANDS VGL101 PHASE 1 TRIAL TO
AUSTRALIA
    * VIGIL NEUROSCIENCE - RECEIVED APPROVAL FROM HUMAN RESEARCH
ETHICS COMMITTEE IN AUSTRALIA TO INITIATE A PHASE 1 TRIAL OF
VGL101 IN HEALTHY VOLUNTEERS
    * VIGIL NEUROSCIENCE INC - CONSIDERING ADMINISTRATION OF A
30
MG/KG DOSE IN VGL101 PHASE 1 TRIAL IN U.S.
    * VIGIL NEUROSCIENCE - REMAIN ON TRACK TO REPORT TOPLINE
DATA FROM
VGL101 PHASE 1 HEALTHY VOLUNTEER TRIAL AND TO INITIATE PHASE 2
TRIAL IN ALSP IN Q4

Source text for Eikon:  ID:nGNX2vglzq 
Further company coverage:  VIGL.O 

 ((Reuters.Briefs@thomsonreuters.com;))